文献速递基础与转化研究临床试验与 GCP

CAR-T细胞治疗首程的临床经验教训

Clinical lessons learned from the first leg of the CAR T cell journey.
PubMed 文献 · Nat Med · 2019-09-09

该综述总结了CAR-T细胞治疗B细胞恶性肿瘤的临床经验,指出其疗效超出预期并推动大量临床试验及美国FDA首批癌症细胞疗法批准。文章归纳了影响CAR-T疗效的CAR内在变量、肿瘤耐药机制及与疗效和耐药相关的因素,并讨论这些见解如何驱动包括实体瘤在内的下一代临床试验。

要点

  • CAR-T治疗B细胞恶性肿瘤的疗效超出预期,已获美国FDA批准用于癌症治疗。
  • 已明确影响T细胞行为的主要CAR内在变量,肿瘤耐药机制日益清楚。
  • 综述经验涵盖B细胞恶性肿瘤等,强调疗效、耐药及成功主要障碍相关因素。

核心结论

  • CAR-T细胞治疗B细胞恶性肿瘤的临床经验已揭示CAR-T疗效的可推广要求以及疾病生物学与临床结局之间的相互作用。

研究设计与样本

  • 综述性文章,回顾迄今为止积累的CAR-T细胞临床经验,涵盖但不限于B细胞恶性肿瘤。

主要发现

  • CAR-T细胞治疗B细胞恶性肿瘤已超越预期,推动临床试验数量持续扩大,并促成美国FDA首批癌症细胞疗法批准。
  • 已定义影响T细胞行为的主要CAR内在变量,肿瘤耐药机制日益被理解。

临床怎么用

  • 文章讨论上述见解如何驱动下一代临床试验,包括实体瘤临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of cell therapies for the treatment of cancer. This experience has illuminated some generalizable requirements for CAR T cell efficacy as well as the interplay between disease biology and clinical outcomes. Major CAR intrinsic variables affecting T cell behavior have been defined, and mechanisms of tumor resistance are increasingly understood. Here, we review the clinical experience with CAR T cells amassed to date, including but not limited to B cell malignancies, emphasizing factors associated with efficacy, resistance and major barriers to success. We also discuss how these insights are driving next-generation clinical trials, including those in solid tumors.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med. 2019. PMID: 31501612. doi:10.1038/s41591-019-0564-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。